JPRN-UMIN000017100已完成未知
Bevacizumab for recurrent or refractory malignant glioma - Bevacizumab for recurrent or refractory malignant glioma
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)ICH, =< 6 month after stroke 2)severe wound, ulcer, fracture 3)bleeding 4) >= 6 month after myocardiac infarction or pulmonary embolism 5)heart failure >= NYHA grade 2 6)uncontrollable hypertention 7)uncontrollable gastric ulcer 8)=< 1 year after gastrointestinal perforation 9)pregnant or conducting breastfeeding 10)already treated by Bevacizumab in the past
研究者
相似试验
进行中（未招募）
不适用
Bevacizumab as treatment for patients with relapsed/refractory multiple myeloma - Avastin in MMMultiple myeloma, relapsed/refractory after at least 2 lines of prior therapyEUCTR2006-000026-31-ATRoche Austria GmbH43
进行中（未招募）
不适用
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program.metastatic colo-rectal carcinomaMedDRA version: 6.1Level: PTClassification code 10061045EUCTR2004-000315-26-ITROCHE1,500
进行中（未招募）
1 期
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program. - First BEATMetastatic cancer of the colon or rectum.EUCTR2004-000315-26-SKF.Hoffmann-La Roche Ltd.2,000
进行中（未招募）
不适用
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program. - First BEATMetastatic cancer of the colon or rectum.EUCTR2004-000315-26-HUF. Hoffmann-La Roche Ltd.2,000
进行中（未招募）
1 期
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum.Metastatic cancer of the colon or rectum.EUCTR2004-000315-26-ESF. Hoffmann-La Roche Ltd.2,000